The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.

Global stock markets and U.S. stock futures rose after a slightly lower close on Wall Street on Tuesday, while the U.S. dollar remained under pressure as expectations build for a potential Federal ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Novo Nordisk, the maker of Wegovy, plans to cut costs and refocus commercially after a $95 billion stock loss. The company's market cap has dropped to around $212 billion.

Maziar Mike Doustdar will take the helm as CEO tomorrow, with the firm facing tough questions from investors about how it can stay competitive.

Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit ...

All three major U.S. indexes finished in the red, after a disappointing services-sector report and tariff news weighed on investor sentiment. The ISM services-sector index provided another sign that ...

Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S ...

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...